Orion

Orion Liabilities

The The Liabilities of Orion (271560.KS) as of Nov 13, 2026 is 686.46 B KRW. In the previous year, The Liabilities was 734.40 B KRW — a change of -6.53% (lower).

Liabilities

686.46 BKRW

YoY

-6.53%

Last updated:

In 2025, Orion's total liabilities amounted to 686.46 B KRW, a -6.53% difference from the 734.40 B KRW total liabilities in the previous year.

The Orion Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
906.81 B KRW
Jan 1, 2019
784.76 B KRW
Jan 1, 2020
767.90 B KRW
Jan 1, 2021
827.88 B KRW
Jan 1, 2022
732.46 B KRW
Jan 1, 2023
565.91 B KRW
Jan 1, 2024
734.40 B KRW
Jan 1, 2025
686.46 B KRW
The Orion Liabilities history
YEARLiabilitiesYoY
686.46 BKRW-6.53%
734.40 BKRW+29.77%
565.91 BKRW-22.74%
732.46 BKRW-11.53%
827.88 BKRW+7.81%
767.90 BKRW-2.15%
784.76 BKRW-13.46%
906.81 BKRW-0.69%
913.09 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orion Stock analysis

What does Orion do? Orion Corp is a Finnish company that operates in the pharmaceutical industry. The company was founded in 1917 and is headquartered in Espoo, Finland. Orion Corp specializes in the development, manufacturing, and marketing of medications, as well as the diagnosis and treatment of diseases. As one of the leading pharmaceutical companies in Finland, Orion Corp is dedicated to researching and developing medications and medical devices to help doctors and their patients worldwide improve their quality of life. Orion Corp's business model focuses on selling prescription and over-the-counter medications, as well as manufacturing generic medications. Additionally, the company is involved in the diagnosis and treatment of diseases such as Parkinson's, cancer, and asthma. The company's main business is centered around three main divisions: pharmaceuticals, diagnostics, and animal health. Within these divisions, Orion Corp has various business areas. In the pharmaceutical division, the focus is on developing medications to combat Parkinson's, cancer, and asthma. The company has a strong product range of Parkinson's treatments that can alleviate symptoms and slow the progression of the disease. Furthermore, the company is involved in the development of cancer medications that can inhibit the growth of cancer cells. Orion Corp is also a key player in asthma treatment. The company produces medications that expand the airways and make breathing easier. In the diagnostics division, Orion Corp's main business is the development and manufacturing of diagnostic devices for diseases such as lung cancer and asthma, as well as products for monitoring blood sugar and cholesterol. Animal health is another important business area for Orion Corp. The company manufactures medications and accessories for animal health and offers a variety of products to veterinarians and breeders. These include, for example, animal vaccines or hormone preparations to increase fertility in animals. Orion's production facilities are located in six countries, including Finland, Germany, France, Russia, the USA, and India. Production within the company primarily takes place in Finland. In addition to manufacturing medications and medical devices, Orion Corp is also a leading producer and developer of raw materials and intermediates for pharmaceutical applications worldwide. In summary, Orion Corp offers a wide range of products and services in the health and animal health fields using the latest scientific knowledge and technologies. The company remains committed to continuously expanding its product and service portfolio and providing patients worldwide with high-quality and effective medications that positively impact their lives. Orion is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Orion's Liabilities

Orion's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Orion's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Orion's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Orion's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Orion’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Orion stock

The Liabilities of Orion is 686.46 B KRW in 2025.

The Liabilities of Orion changed from 734.40 B KRW to 686.46 B KRW, representing a -6.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Orion since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Orion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Orion

All Key Metrics — Orion